Failla Cristina Maria, Carbone Maria Luigia, Ramondino Carmela, Bruni Emanuele, Orecchia Angela
Experimental Immunology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.
Clinical Trial Center, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.
Biomedicines. 2024 Dec 24;13(1):6. doi: 10.3390/biomedicines13010006.
The vascular endothelial growth factor (VEGF) family includes key mediators of vasculogenesis and angiogenesis. VEGFs are secreted by various cells of epithelial and mesenchymal origin and by some immune cells in response to physiological and pathological stimuli. In addition, immune cells express VEGF receptors and/or co-receptors and can respond to VEGFs in an autocrine or paracrine manner. This immunological role of VEGFs has opened the possibility of using the VEGF inhibitors already developed to inhibit tumor angiogenesis also in combination approaches with different immunotherapies to enhance the action of effector T lymphocytes against tumor cells. This review pursues to examine the current understanding of the interplay between VEGFs and the immune system, while identifying key areas that require further evaluation.
血管内皮生长因子（VEGF）家族包括血管生成和血管新生的关键介质。VEGF由上皮和间充质来源的各种细胞以及一些免疫细胞在生理和病理刺激下分泌。此外，免疫细胞表达VEGF受体和/或共受体，并能以自分泌或旁分泌方式对VEGF作出反应。VEGF的这种免疫学作用为将已开发的VEGF抑制剂与不同免疫疗法联合使用以增强效应T淋巴细胞对肿瘤细胞的作用开辟了可能性。本综述旨在探讨目前对VEGF与免疫系统之间相互作用的理解，同时确定需要进一步评估的关键领域。
